Aspirin blocks EGF-stimulated cell viability in a COX-1 dependent manner in ovarian cancer cells

Journal of Cancer

Volumn 4, Issue 8, 2013, Pages 671-678

  Cho, May ^a   Kabir, Syeda M ^b   Dong, Yuanlin ^b   Lee, Eunsook ^b   Rice, Valerie Montgomery ^c   Khabele, Dineo ^d   Son, Deok Soo ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c MOREHOUSE COLLEGE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Akt; Aspirin; Cell viability; COX 1; EGF; Erk; Ovarian cancer

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER RISK; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; EXPRESSION VECTOR; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; RISK REDUCTION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84885462303     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7118     Document Type: Article

References (33)

1. Chobanian N, Dietrich CS. Ovarian cancer. Surg Clin North Am. 2008; 88: 285-99.
2. Sudo T. Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol. 2012; 17: 424-9.
3. Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012; 58: 133-47.
4. Pejovic T, Nezhat F. Missing link: inflammation and ovarian cancer. Lancet Oncol. 2011; 12:833-4.
5. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993; 90:11693-7.
6. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2013; doi: 10.1002/pds.3463. [Epub ahead of print]
7. Shebl FM, Sakoda LC, Black A, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer. 2012; 107: 207-14.
8. Veitonmäki T, Tammela TL, Auvinen A, et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013; 49: 938-45.
9. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012; 23: 1403-15.
10. Johnson CC, Hayes RB, Schoen RE, et al. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J Gastroenterol. 2010; 105: 2646-55.
11. Neill AS, Nagle CM, Protani MM, et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: A case-control study, systematic review and meta-analysis. Int J Cancer. 2013; 132: 1146-55.
12. Murphy MA, Trabert B, Yang HP, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012; 23: 1839-52.
13. Ni X, Ma J, Zhao Y, et al. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol. 2013; 75: 26-35.
14. Setiawan VW, Matsuno RK, Lurie G, et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: The Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1441-9.
15. Ammundsen HB, Faber MT, Jensen A, et al. Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. Acta Obstet Gynecol Scand. 2012; 91: 1094-102.
16. Lo-Ciganic WH, Zgibor JC, Bunker CH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012; 23: 311-9.
17. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010; 19: 435-42.
18. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003; 63: 906-11.
19. Daikoku T, Tranguch S, Trofimova IN, et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006; 66: 2527-31.
20. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005; 65: 3735-44.
21. Li W, Ji ZL, Zhuo GC, et al. Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice. Med Oncol. 2010; 27: 98-104.
22. Daikoku T, Tranguch S, Chakrabarty A, et al. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res. 2007; 67: 5285-92.
23. Son DS, Wilson AJ, Parl AK, et al. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther. 2010; 9: 928-35.
24. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
25. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.
26. Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008; 18: 879-90.
27. Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 2012; 36: 490-6.
28. Wilken JA, Badri T, Cross S, et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem. 2012; 4: 447-69.
29. Nordt SP, Clark RF, Castillo EM, et al. Comparison of three aspirin formulations in human volunteers. West J Emerg Med. 2011; 12: 381-5.
30. Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010; 2010: 568938.
31. Uddin S, Ahmed M, Hussain A, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010; 126: 382-94.
32. Zhang W, Sun HC, Wang WQ, et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012; 143: 1641-9.
33. Lu L, Sun HC, Zhang W, et al. Aspirin minimized the pro- metastasis effect of Sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One. 2013; 8: e65023.